The Problem
Current drug discovery methods primarily rely on target-first approaches and synthetic molecule libraries that are associated with high clinical trial failure rates due to lack of efficacy.
The Pragma Bio Solution
At Pragma Bio, we discover new medicines using our biology-first approach that :
- Mines a clinically-relevant source of small molecules
- Uses phenotypic screens to uncover new disease-modifying pathways and targets
- De-risks efficacy early in development
The Opportunity
The Gut-Immune Axis (GIA) plays an essential role in health and disease by coordinating interactions between the immune system and gut microbes.
This GIA coordination is mediated via small molecules produced by gut-residing microbes. The instruction manuals for these immune-regulating molecules are the Biosynthetic Gene Clusters (BGCs) found on the microbial genome.
.svg)
The small molecules made using the BGC instruction manual have co-evolved with humans and can be the source of many new medicines.
Our Platform - PICASSO
At Pragma Bio, we have built a biology-first, AI-enabled platform for mining, making, and testing novel gut-derived small molecules to create effective new medicines.
Bioinformatics & AI
Mine clinically-relevant BGCs for specific diseases using Real World Evidence (RWE) and multi-omics datasets.
SynBio & MedChem
Make, analyze, and derivatize those BGCs and their small molecule products using cutting-edge synthetic biology and chemistry tools.
Pharmacology
Test molecules in models of disease biology to select candidates for further optimization and characterization and to decipher the molecular target and mechanism of action.
.svg)
What makes us different
End-to-end data-to-molecule discovery pipeline powered by best-in-class BGC database
Promoting speed, standardization, failing-fast
Proprietary expertise in small molecule synthesis
Generating patentable novel molecules for New Chemical Entity (NCE) optimization
De-risked starting points for novel medicines
Mining a source of naturally evolved molecules enriched with immune system modulators
Automated, AI-based, adaptive BGC platform
Building the smartest, ever-evolving BGC-to-molecule pipeline and database mining tools
Our team
Our team
Our Investors
We are profoundly supported by top tier investors and strategic partners
Partner with us
Our network includes some of the leading biopharma and research organizations. Reach out to explore possible collaborations and synergies!
Partner with us
Latest news
